Markey Gains National Hematology Experts

Contact: Louise DuPont

 

""

McDonagh is an expert in blood disorders and immunology. His research is funded by grants from the National Cancer Institute, the American Cancer Society, and the Leukemia and Lymphoma Society.

Rinehart’s areas of interest include developmental therapeutics and cancer treatment with biologic agents and/or immunotherapy; his major focus at UK will be in the treatment of patients with lung and urological cancers.

""

LEXINGTON, Ky. (Dec. 2, 2004) -- Two nationally known physicians have been appointed to help lead the University of Kentucky Markey Cancer Center to the forefront of cancer research and treatment.

Dr. Kevin McDonagh, a research physician-scientist, will take the lead as the chief of the Division of Hematology, Oncology, and Blood and Marrow Transplantation in the Department of Internal Medicine in the UK College of Medicine. In addition, McDonagh will be deputy director of the Markey Cancer Center and the Markey Foundation Chair in Oncology Research.

Dr. John Rinehart has been appointed associate director for clinical research for the Markey Cancer Center and director of clinical oncology and clinical research in the Division of Hematology, Oncology, and Blood and Marrow Transplantation. He has also been appointed the Buck–Kentucky Lung Cancer Research Chair.

McDonagh comes to UK from the University of Michigan, a National Cancer Institute designated Comprehensive Cancer Center, to lead expansion of the cancer program.

“I was drawn to UK because of the outstanding clinical and research programs at Markey, as well as the strong commitment of the institution to invest in new faculty and research programs. Our goal is to provide patients with state of the art care and service,” said McDonagh.

McDonagh is an expert in blood disorders and immunology. His research is funded by grants from the National Cancer Institute, the American Cancer Society, and the Leukemia and Lymphoma Society. He is a member of several federal peer review grant review panels. While at Michigan as a member of the National Comprehensive Cancer Network, McDonagh helped to write national standards for the diagnosis and treatment of non-Hodgkin’s lymphoma.

McDonagh’s clinical efforts at UK will focus on treatment of patients with hematologic malignancies such as leukemia, lymphoma and myeloma.

Rinehart comes to UK from the University of Alabama at Birmingham’s National Cancer Institute designated Comprehensive Cancer Center where he served as the director of the Division of Hematology and Oncology, associate director of Clinical Research, and the Martha Ann and David L. May Endowed Chair of Cancer Research.

Rinehart was a faculty member at Ohio State University in Columbus and a member of its Comprehensive Cancer Center from 1978 to 1990. He served as Division of Hematology/Oncology director at Texas A&M University from 1990 to 1998. He organized and became the first director of the Texas A&M Cancer Center and the Scott-White Clinic from 1993 to 1998.

He received his Bachelor of Arts and medical degrees from Ohio State University, where he was elected to Phi Beta Kappa. Rinehart completed his medical internship at Ohio State, his residency at the University of Chicago, and a fellowship at Ohio State University.

Rinehart’s areas of interest including developmental therapeutics and cancer treatment with biologic agents and/or immunotherapy; his major focus at UK will be in the treatment of patients with lung and urological cancers.

If you would like an appointment with either of these physicians, please call the Markey Cancer Center at (866) 340-4488 or 257-4488.


Back to Campus News Homepage